Lumeon wins MedTech Breakthrough Award - Gilde Healthcare

Lumeon wins MedTech Breakthrough Award

6. Juni 2017

LONDON AND NEW YORK – Lumeon, a leading digital health company, has won the MedTech Breakthrough Award for Best Overall Health Administration Software. The awards recognize the top companies, people, platforms and products in the global health and medical technology market today.

Lumeon’s Care Pathway Management (CPM) platform, that allows providers to automate and orchestrate workflows across the care continuum, impressed the judges with its capability to digitize risk reducing strategies, improve efficiency and scale best practice.

Robbie Hughes, Lumeon’s CEO said, “Alternative payment models are prompting the industry to think differently about the way care is delivered and how we collaboratively manage risk to deliver better quality outcomes. Providers want better visibility into outcomes data across the care continuum, as well as innovative ways of engaging patients and managing healthcare administration. I’m delighted to accept this award as we continue to deliver solutions that are both personalized and scalable.”

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories. This year’s program attracted more than 2,000 nominations from over 10 different countries throughout the world. All nominations were evaluated by an independent panel of experts within the medical and health industry.

“We are pleased to recognize Lumeon among the MedTech Breakthrough Awards this year,” stated James Johnson, Managing Director at MedTech Breakthrough. “Health administration can be an extremely complex proposition for healthcare providers, taking focus away from the ultimate goal of improving patient care. By automating and simplifying health workflows with software such as Lumeon’s Care Pathway Management platform, we see tremendous benefits for healthcare providers and patients alike. Congratulations to the entire Lumeon team on their industry recognition.”

Gilde Healthcare company CatalYm announces leadership changes to accelerate visugromab late-stage clinical development

Gilde Healthcare company CatalYm, a world-leader in neutralizing GDF-15 in cancer and cachexia, today announced changes to its executive leadership team to support its next stage of growth. The appointments of Clinton Musil as Chief...
15. September 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of tumor...
10. September 2025

Gilde Healthcare ernennt Dr. Christian Stark zum Group CEO ihrer global operierenden Medizintechnikgruppe

Die Medizintechnikgruppe, zu der zwei Hersteller chirurgischer Instrumente aus der Region Tuttlingen gehören, Koscher & Würtz und Christian Diener, hat Dr. Christian Stark mit Wirkung zum 1. September 2025 zum Chief Executive Officer (CEO) berufen....
3. September 2025